Comparison of cernitin pollen extract and tadalafil in the treatment for benign prostatic hyperplasia with chronic prostatitis: A randomized, prospective study

Comparison of cernitin pollen extract and tadalafil in the treatment for benign prostatic hyperplasia with chronic prostatitis: A randomized, prospective study - Comparison of cernitin pollen extract and tadalafil in the treatment for chronic prostatitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027420

Enrollment

100

Registered

2017-06-01

Start date

2017-07-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia with chronic prostatitis

Interventions

cernitin pollen extract 4T per day for 12 weeks tadalafil(5mg) 1T per day for 12 weeks

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: (1) patinets who take orally alpah 1 blocker for more than 12 weeks for benign prostatic hyperplasia (2) NIH-CPSI pain domain score 4 or more (3) age: more than 45 years (4) outpatients

Exclusion criteria

Exclusion criteria: Patients were excluded if they received oral or surgical treatment except alpha 1 blocker for lower urinary tract symptoms; or had neurogenic bladder dysfunction, bladder calculi, or active urinary tract infections and prostatitis; or had severe cardiac disease, renal dysfunction, or hepatic dysfunction.

Design outcomes

Primary

Measure	Time frame
change of the subjective symptoms regarding chronic prostatitis	—

Secondary

Measure	Time frame
change of the subjective symptoms regarding lower urinary tract symptome	—

Countries

Japan

Contacts

Public ContactYoshihisa Matsukawa

Nagoya University Graduate School of Medicine Department of Urology

yoshi44@med.nagoya-u.ac.jp052-744-2985

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026